TSLA chart above
QQQ chart above
As we last left off, TSLA rose on yet another Monster Monday, followed quickly by a Tremendous Tuesday that built upon those gains. To no one's great surprise, these trading days were followed by Weak Wednesday as TSLA gave up ground to weak macros and then Manipulator's Thursday in which TSLA lost far more than the macros as option sellers pulled TSLA down at more than a 2X multiple to the NASDAQ in an effort to set up Friday for a further pushdown on a Triple Witching Options Expiration day. I stated that I planned to buy Friday afternoon at the low in order to play the Friday to Monday trade and the anticipated buildup to Battery Day trade (keep in mind my trades are a very small portion of my TSLA holdings, the majority of which are just HODL holdings that change in leverage over time).
I almost laughed out loud when I saw Friday morning's trading. Despite a NASDAQ that sagged well into the red after 11am, some big dog was lapping up shares prior to Battery Day, like there was no tomorrow. I think it became obvious to the big dog(s) that traders such as myself were ready to buy in Friday afternoon to take advantage of a run higher on Monday, and so they did the logical thing: they beat us to the punch. That's okay, my core shares did well. At about 2pm, after the NASDAQ had bottomed out with a dip around 2.7% and TSLA was still well in the green, I bought a trading leap for Monday's expected rise. Lately I've been buying as early as 2pm on Friday's to beat the traders rushing in to buy during the final hour. That flurry of late Friday buying did indeed come as TSLA flirted with 450 12 minutes before market close. From there on, the option sellers sold hard to sink TSLA in the final minutes. Notice there was no news nor macro movement to justify the dip.
Looking at volume, we saw no less than 2.6 million shares trade during first minute of market trading and nearly 5.5 million shares trade during the 4:00pm minute. Mercy! I think the big 4:00pm buy was likely led by market makers and other option sellers who manipulated the stock down in the final 12 minutes and then tried as hard as possible to buy back at 4:00pm to get closer to delta-neutral. I suspect they are still in need of some buying to get delta-neutral and so we may see some upward pressure from delta-hedge buying Monday morning. Overall volume was rather light at 84 million shares traded, particularly in light of TSLA's 4.4% climb. Interpretation? Investors weren't in a hurry to sell and so a large price increase on a day with negative macros was needed for the big dog(s) to buy a substantial number of shares prior to Monday. Needless to say, unless macros are really in the dumpster on Monday I suspect TSLA rises nicely.
All eyes are on Battery Day, which begins after the Tesla Annual Meeting on Tuesday. Although a majority of events at Tesla have led to sell the news responses from the market, I believe the potential is there for the results of Battery Day to move the stock price higher. My overriding theory is that if there's a sale the news response, you just ride out the dip and TSLA goes up on other good news which appears to be coming soon (3rd and 4th quarter Production and Delivery Reports and ERs). There's also the wild card of S&P500 inclusion out there. If Battery Day turns out to provide enough material to plug into analyst spreadsheets and move the stock price noticeably higher, I want to be in, and someone sitting on the sidelines may never get another buying opportunity at this price point. There's no certainties with things Tesla, but when in doubt I get my best results with HODL for the long term.
* Rob Maurer did a good job
here at previewing what may be coming at Battery Day
* TMC member
@gabeincal did a great job here at showing the Fremont factory from a drone's eye view
One concern of some investors is whether TSLA is too far ahead of the NASDAQ after September's macro weakness. Here's how I see it. If you look at TSLA's stock price change from its August 31 high of 498 to its Friday close at 442, that's a dip of about 11.5%
If you look at the NASDAQ dip on those same days, the dip works out to be about 8.4%. In other words, TSLA's dip over those days is still greater than the NASDAQ's. Moreover, I think the exaggerated dip of TSLA in the first two days of September may have actually been a catalyst for the NASDAQ dip.
Coronavirus
Another concern of investors for the coming week is Coronavirus.
As you can see from the chart above, the past week has seen a momentum change in the U.S. from decreasing new cases numbers to increasing numbers. My guess is that much of this increase in new cases is due to college students being too lax about social distancing. As with other increases, I think the problem will be identified and corrected.
If you look at deaths in the U.S., the second wave included higher "new cases" numbers than the first, but the deaths bump has been considerably lower than the first wave. I attribute better treatments and better protection of the vulnerable elderly for this improvement.
Nonetheless, investors are looking at an outbreak in Europe as something to possibly worry about. Let's take a look at France and Spain.
As you can see, the second wave in France is still accelerating and is quite a bit larger than the first.
Nonetheless, look at how much better the deaths are being reduced during this second wave. Granted, the deaths follow the new cases by 3 or more weeks of time, so we have to wait a while to see the results, but overall the virus is being treated better in recent months than during the first wave. At least for this week, the deaths in France should not be a hindrance to the market.
Looking at spain, the second wave reached numbers similar to the first, but look at the drop off in new cases this past week. As we have seen elsewhere, new waves are met with new procedures for dealing with them, which can lead to a dip such as we see in Spain.
Overall, I am disappointed so far in the ability of world authorities to deal with the coronavirus. My disappointment focuses in particular on treatment options in the United States. Let's review the biases of the various parties:
Trump administration- The POTUS has placed his biggest bet on a viable vaccine. With billions paid up front to get manufacturing underway even before a single vaccine has been proven safe, the strategy is apparent and has a reasonable chance of working. Nonetheless, the bias would be against therapeutics that treat active cases because the POTUS scores political points if it turns out that a vaccine and not an inexpensive and readily available combination of drugs wins the battle.
Democratic opposition- The Democrats don't want a vaccine approved and offered to the American people before the election. Some of the concerns are justified, in that we don't want to see a vaccine in the wild that has serious side effects. The other side of the concern is simply politics at work, trying to introduce fear of vaccines. At some point, they're going to have to undo that induced fear, which is not a good thing. Fortunately, the major U.S. vaccine makers utilize independent groups of experts who control the safety of the vaccine trials. The vaccine isn't proclaimed safe until the independent groups weigh in. Neither the POTUS nor the CEO of the company can hurry the vaccine beyond the pace the groups over overseeing experts wish to see, and so fears of a "rushed" vaccine are likely overstated.
The FDA- Here's my biggest disappointment. When it comes to testing, the FDA tends to err on the side of avoiding false negatives. Some of the molecular tests are so amplified that they're producing false positives as tiny bits of material from a prior infection are exaggerated to the point of showing a positive result. Most of these tests are somewhat expensive and require days before the lab has the verdict. A better approach in my mind would be cheap, readily available home tests that could yield an answer in 15 minutes. We see a number of both saliva and nose swab tests developed, but we're not seeing FDA approval of these tests. My guess is that they're not as sensitive as the other tests (which not-so-coincidentally are the primarily the products of big pharma) and they might only catch 90% of cases. Guess what? As long as the limitations of these tests are known, 90% is good enough for everyday testing. The speed of the testing is key and can eliminate a lot of transmission. The speed of catching cases early is particularly important when combined with my second point.
The second FDA bias is in favor of big pharma. We're seeing hugely encouraging small studies get ignored because they're not backed by big pharma. One group is the studies of HCQ, Zinc, and Azithromycin to treat at risk individuals who have just contracted the disease. If the disease can be stopped before the storm battle in the lungs begins, this disease becomes manageable. Unfortunately, we don't see follow-up major trials to confirm the findings of small studies, and since the medical community insists on the big, double-blind studies as the gold standard, promising treatments that don't involve big pharma don't get moved into mainstream use in the U.S. A second highly-encouraging discovery is that a type of highly-potent Vitamin D has been shown in a small study in Spain to hugely cut the number of patients who progress to the ICU.
Here's the sensational version of the study and
here's the more scientifically-oriented version.
If one of the vaccine candidates proves safe and becomes available within the next couple months, then it's likely game over for the coronavirus as those taking the vaccine will likely be of sufficient numbers in time to provide herd immunity to the population. In the meantime, I continue to be frustrated with the unreasonable avoidance of reproducing promising small studies so that we can confirm that inexpensive and potent treatment options are available. When you combine these treatment options with inexpensive home test kits, the end of coronavirus would be at hand. Too many of the FDA and other government decisions are too heavily skewed in favor of big pharma and away from promising less-profitable solutions.
Looking at the tech chart, you can see TSLA having returned well within the mid-bollinger band to upper-bollinger band range.
For the week, TSLA closed at 442.15, up 69.43 or 18.6% from last Friday's 372.72. It's been a great week and I hope you've enjoyed your weekend. Snug up the seatbelt because Battery Day is coming Tuesday.
Conditions:
* Dow down 245 (0.88%)
* NASDAQ down 117 (1.07%)
* TSLA 442.15, up 18.72 (4.42%)
* TSLA volume 84.4M shares
* Oil 41.11
* Percent of TSLA selling tagged to shorts: 37%